Korea may hail its first-ever novel blockbuster drug this year
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Hanmi Pharmaceutical and Yuhan Corp. have filed for FDA approval for their non-small cell lung cancer (NSCLC) treatments. Because none of NSCLC treatment has received FDA approval yet, one of their drugs could be Korea’s first FDA-approve blockbuster drug if granted.
Hanmi Pharmaceutical licensed out its NSCLC treatment, Poziotinib, to U.S.-based Spectrum Pharmaceuticals in February 2015. Hanmi Pharm submitted a New Drug Application (NDA) for poziotinib to the FDA on Jan. 7.
Yuhan’s NSCLC treatment, lazertinib, was originally developed by Oscotec Inc. and was licensed out to Yuhan Corp. in 2015 and then sublicensed globally to Janssen in 2018 for 1.4 trillion won ($1.1 billion). If lazertinib receives FDA approval, Yuhan will receive a milestone payment of 200 billion won from Janssen.
Janssen is currently conducting Phase 3 clinical trials for lazertinib and amivantamab combination therapy. If it is granted a fast-track designation, it may receive FDA approval within this year.
GC Pharma’s plasma-derived immunodeficiency drug, IVIG-SN, is also garnering attention. The FDA previously rejected the license application for IVIG-SN, asking the company to provide supplementary information on the drug’s manufacturing procedures. IVIG-SN currently accounts for 36 percent of GC Pharma’s total sales.
IVIG-SN is an immunoglobulin formulation made by separating and purifying certain proteins from plasma, the fluid part of blood, and is used to treat primary immunodeficiency diseases (PIDDs) such as congenital immunodeficiency and immunodeficiency. In February last year, GC Pharma filed for FDA-approved indication for IVIg-SN 10% use in primary immunodeficiency. The FDA approval decision will be announced late next month, and if granted FDA approval, IVIG-SN will lead the American immunoglobulin drug market which is worth 10 trillion won.
Another Korean pharmaceutical company Mezzion Pharma may release the world’s first Fonton treatment. Mezzion Pharma submitted an NDA application to the FDA for Udenafil, a treatment for patients 12 years of age and older who have undergone the Fontan operation for single ventricle heart disease (SVHD). Udenafil has been granted a priority review which will shorten the FDA's review of the application to six months.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- SSG.Com to open second-hand luxury goods platform, premium shipping service this year - Pulse by Maeil Business News Korea
- Cyclical, financial, energy stocks attractive during tightening: New York Life CIO - Pulse by Maeil Business News Korea
- K Auction kicks off first day on Kosdaq with a double win - Pulse by Maeil Business News Korea
- Korean backers’ SPAC targeting life science, ESG readies $200 mn IPO on Nasdaq - Pulse by Maeil Business News Korea
- Naver CEO Han Seong-sook likely to lead e-commerce expansion in Europe - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- [CEO lounge]주류업계 고졸신화 장인수 오비맥주 신임 사장…바닥영업으로 맥주명가 재건
- 김희철, 일본 유흥 루머 강력 반박 “SM 후배들과 술도, 연락도 안 해” - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이